The mechanism of action of bevacizumab includes binding to circulating VEGF-A and blocking of VEGF-A binding to its receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, which results in the inhibition of tumor angiogenesis, growth, and metastases [18]. The gene discussed is VEGFA; the disease is neoplasm.